A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes Post author:admin Post published:February 18, 2025 Post category:uncategorized Post comments:0 Comments New research shows sotagliflozin is the only drug in its class to demonstrate these results. You Might Also Like Study finds substantial racial disparities in opioid prescribing for pain November 2, 2023 New AI system achieves 98.5% accuracy in autism diagnosis November 21, 2023 Early smoking causes structural and functional heart damage December 11, 2024 Leave a Reply Cancel replyYou must be logged in to post a comment.